The Effects of Remifentanil on Attenuating the Hemodynamic Responses After Electroconvulsive Therapy

Inonu University, Turgut Ozal Medical Center, Department of Anesthesiology and Reanimation Malatya

Status

UNKNOWN

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02271555

Enrollment

Registered

2014-10-22

Start date

2014-10-31

Completion date

2014-12-31

Last updated

2014-10-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Haemodynamic Rebound

Keywords

electroconvulsive therapy, sevoflurane, remifentanil

Brief summary

The investigators will be evaluated the effects of a single loading dose of remifentanil (1µg/kg), administered as an adjunct to sevoflurane, on duration of hemodynamic profile, seizure activity, and recovery times during electroconvulsive therapy (ECT) in patients with major depression

Detailed description

Major depressive patients will enrolled this trial. Mean arterial pressure (MAP) and heart rate (HR) and peripheral oxygen saturation values will be recorded prior to anesthetic induction (T1); following anesthetic induction (T2); and 0, 1, 3, and 10 minute after the seizure have ended (T3, T4, T5, and T6, respectively). The peak heart rate during the seizure will be recorded from the Electrocardiogram.

Interventions

DRUGSevoflurane

Anesthetic induction will be achieved via 8% sevoflurane

DRUGRemifentanil

After the loss of consciousness remifentanil will be administered to Group sevoflurane-remifentanil in the form of a 1 µg/kg intravenous bolus.

DRUGSaline

After the loss of consciousness saline will be administered to Group sevoflurane-saline intravenous bolus.

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

DOUBLE (Investigator, Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

18 Years to 60 Years

Healthy volunteers

Inclusion criteria

* Major depressive patients

Exclusion criteria

* younger than 18 years, pregnant, had a history of myocardial infarction in the previous six months, atrial fibrillation or flutter, heart block, unregulated hypertension, cerebrovascular diseases, known drug allergy.

Design outcomes

Primary

Measure	Time frame	Description
The effects of remifentanil on the heart rate after electroconvulsive therapy	20 minute	Prior to anesthetic induction (T1); following anesthetic induction (T2); and 0, 1, 3, and 10 minute after the seizure have ended (T3, T4, T5, and T6, respectively).

Secondary

Measure	Time frame	Description
Seizure duration	20 minute	During electroconvulsive therapy
The effects of remifentanil on the mean arterial pressure after electroconvulsive therapy	20 minute	Prior to anesthetic induction (T1); following anesthetic induction (T2); and 0, 1, 3, and 10 minute after the seizure have ended (T3, T4, T5, and T6, respectively).

Countries

Turkey (Türkiye)

Contacts

Primary ContactFeray Erdil, MD

feray.erdil@inonu.edu.tr+90 422 341 06 60

Backup ContactMahmut Durmus, MD

mahmut.durmus@inonu.edu.tr+90 422 341 06 60

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026